CVS Agrees to $37.8 Million Settlement Over Insulin Pen Claims

CVS Health Agrees to $37.76 Million Settlement Over Insulin Pen Dispensing Practices

CVS Health will pay $37.76 million to resolve allegations that it improperly dispensed excess insulin pens to patients and then obtained unwarranted reimbursements from government healthcare programs, according to U.S. Attorney Jay Clayton in Manhattan.

The settlement, announced Tuesday, concludes a case where CVS was accused of violating the federal False Claims Act over an eleven-year period from January 2010 through December 2020. Federal investigators determined that the pharmacy chain dispensed more insulin pens than physicians had prescribed, secured reimbursements for premature refills, and failed to accurately report the quantity of insulin its pharmacies were dispensing.

According to the settlement, CVS allegedly directed pharmacy staff to report the maximum allowable days-of-supply when dispensing full insulin pen cartons. This practice reportedly ensured prescriptions could be filled as quickly as possible and that reimbursement claims would be approved without delays or rejections from insurers.

The payout structure includes $24.45 million to the federal government, with the remaining $13.31 million distributed among various U.S. states affected by the practices. The settlement resolves both a U.S. Department of Justice lawsuit and several whistleblower cases filed against the company.

The first whistleblower case was initiated in 2018 by Adam Rahimi, a CVS pharmacist who identified the problematic dispensing patterns. Whistleblowers will collectively receive 19.5% of the settlement amount, with Rahimi receiving the majority portion, according to his legal representatives.

In response to the settlement, CVS acknowledged the challenges surrounding insulin pen billing, attributing the issues to various factors that complicated accurate dispensing. “Insulin pen billing has long been a challenge for pharmacies because of labeling changes, variable dosing and packaging, and varying payor supply limits,” the company stated.

The Rhode Island-based pharmacy chain also noted that recent industry developments have helped mitigate some of these challenges. “In recent years, the evolution of PBMs (pharmacy benefit managers) and payor practices to account for insulin pen packaging and other technological enhancements have helped alleviate some of these challenges,” CVS said in its statement. “With this settlement, we’re pleased to put this issue behind us.”

Insulin pens are critical medical devices for diabetic patients, who use them to self-administer insulin injections to manage their blood glucose levels. The proper dispensing of these devices is particularly important given the rising costs of insulin and ongoing concerns about affordability for diabetic patients across the United States.

This settlement comes at a time of increased scrutiny of pharmaceutical pricing and dispensing practices, particularly for essential medications like insulin. In recent years, federal and state authorities have intensified efforts to monitor healthcare billing practices to protect government healthcare programs from improper charges.

The CVS case highlights the critical role whistleblowers play in identifying potential healthcare fraud. Federal whistleblower provisions allow individuals with knowledge of fraud against government programs to file lawsuits on behalf of the government and receive a portion of any recovered funds.

The settlement does not include an admission of liability by CVS, which is standard in many corporate settlements with government agencies. However, the agreement requires the company to implement measures to prevent similar issues from recurring in the future.

The case was part of the government’s broader efforts to combat healthcare fraud, which costs taxpayers billions of dollars annually through improper billings to Medicare, Medicaid, and other government healthcare programs.